PT  - JOURNAL ARTICLE
AU  - Braga, Joeffre
AU  - Kuik, Jie Yi
AU  - Lepra, Mariel
AU  - Rusjan, Pablo
AU  - Kish, Stephen
AU  - Vieira, Erica
AU  - Nasser, Zahra
AU  - Verhoeff, Natasha
AU  - Vasdev, Neil
AU  - Chao, Thomas
AU  - Bagby, Michael
AU  - Boileau, Isabelle
AU  - Kloiber, Stefan
AU  - Husain, Ishrat
AU  - Kolla, Nathan
AU  - Koshimori, Yuko
AU  - Faiz, Khunsa
AU  - Wang, Wei
AU  - Meyer, Jeffrey
TI  - <strong>Astrogliosis marker [11C]SL2511.88 After COVID-19 With Ongoing Depressive and Cognitive Symptoms</strong>
DP  - 2024 Jun 01
TA  - Journal of Nuclear Medicine
PG  - 241475--241475
VI  - 65
IP  - supplement 2
4099  - http://jnm.snmjournals.org/content/65/supplement_2/241475.short
4100  - http://jnm.snmjournals.org/content/65/supplement_2/241475.full
SO  - J Nucl Med2024 Jun 01; 65
AB  - 241475 Introduction: After acute COVID-19, persistent depressive and cognitive symptoms occur in ~5% of cases (COVID-DC). Theoretical models of COVID-DC suggest astrogliosis is important but measures primarily indicative of astrogliosis have not been studied in COVID-DC. Methods: In this case-control study, positron emission tomography (PET) is used to determine if [11C]SL2511.88 total distribution volume (), an index of monoamine oxidase B (MAO-B) density and marker of astrogliosis (outside midbrain) is elevated in COVID-DC. In 21 COVID-DC cases and 21 healthy controls [11C]SL2511.88 VT was measured in prefrontal cortex (PFC), anterior cingulate cortex (ACC), hippocampus, dorsal putamen (DP) and ventral striatum (VS). Depressive and cognitive symptoms were measured with psychological and neuropsychological tests. Data collection and analysis for participants with current major depressive episode without history of COVID-19 is ongoing; n=21 is anticipated at the time of presentation.Results: [11C]SL2511.88 VT was greater in COVID-DC compared to healthy across prioritized regions by ~20% (p=0.001), as well as most grey matter regions. MDE severity, measured by the Beck Depression Inventory-2 negatively correlated with [11C]SL2511.88 VT in PFC, ACC, DP and VS, r=-0.55 (p=0.02) to -0.48 (p=0.04)). The 10 least severe COVID-DC cases had higher [11C]SL2511.88 VT than the 9 most severe across regions of interest by 18% (p=0.01). More recent acute COVID-19 correlated with greater [11C]SL2511.88 VT, r=0.61 (p=0.003) to 0.74 (p=0.0001), reflecting higher values since predominance of the omicron variant.Conclusions: MAO-B labelled astrogliosis occurs throughout grey matter regions in COVID-DC. However, greater astrogliosis associated with lesser symptom severity, raising the possibility of a protective role in COVID-DC, such as combatting infection. Degree of astrogliosis in COVID-DC has not decreased since emergence of omicron variant.